New hope for psoriatic arthritis sufferers: phase 3 trial of sonelokimab launches
Disease control
Recruiting now
This study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not responded well to or cannot tolerate standard TNF-blocker treatments. About 600 participants will receive either sonelokimab, a placebo, or an active reference drug to see if so…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated May 26, 2026 12:09 UTC